Company / Cash & Equivalents
ABEONA THERAPEUTICS INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$78.4M
FY2025
5-year range
$14.2M / $78.4M
FY2021-FY2025
Trend
+235.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +236% YoY in FY2025, a notable deviation from the 9-year average annual change of +118%.
Based on SEC 10-K filings.
$78M in FY2025 with a 5-year CAGR of +44.2%.
Improved from $14M to $78M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +76.7%
- 5-Year CAGR
- +44.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- ABEONA THERAPEUTICS INC.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +44.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 235.8% year-over-year.
- Peak cash & equivalents was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -2.42 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $78.4M | +235.8% |
| FY2024 | $23.4M | +61.4% |
| FY2023 | $14.5M | +1.8% |
| FY2022 | $14.2M | -56.8% |
| FY2021 | $32.9M | +161.5% |
| FY2020 | $12.6M | -90.3% |
| FY2019 | $129.3M | +589.4% |
| FY2018 | $18.8M | -86.4% |
| FY2017 | $137.8M | +243.2% |
| FY2016 | $40.1M | +248.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026